COVID-19 Oral Treatment Briefing February 10, 2022 2:00 PM to 3:00 PM

Please join Pfizer for a conversation with:

Eddie G.M. Power, PhD, MBA, GFMD
Vice President, North America Medical Affairs
Hospital Business Unit, Pfizer

Florin Draica, MD, CMD, MBA
US Senior Medical Director, Anti-Infectives
Hospital Business Unit, Pfizer

Hosted by Molly K. Williams, Dominick Spatafora & Willem Rijksen

Alliance Development and Public Affairs Teams, Pfizer

DATE: Thursday, February 10th

TIME: 2:00 p.m. – 2:45 p.m. ET
Event number: 2590 043 5071
Event password: 9tTuB8wWQa6
Event address for attendees: https://pfizerevents.webex.com/pfizerevents/onstage/g.php?MTID=e4e9e35126ebc6f0f6133f261c5823c94

Audio Conference: This is a listen only service for attendees.

1-650-479-3208 Call-in toll number (US/Canada)
1-877-668-4493 Call-in toll-free number (US/Canada)

Access Code: 2590 043 5071

Pfizer’s oral treatment for COVID-19 has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.

The emergency use of Pfizer’s oral treatment for COVID-19 is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.